Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
Benzinga Newsdesk 1 month ago
News
6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care
6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy
AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting